Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Free Realtime Quote INR

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

Compare
2,896.00
-32.60
(-1.11%)
As of 2:51:09 PM GMT+5:30. Market Open.
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
36,927,008
34,417,708
32,263,787
32,640,812
28,994,059
Cost of Revenue
14,913,685
14,198,485
13,587,230
14,496,539
13,388,156
Gross Profit
22,013,323
20,219,223
18,676,557
18,144,273
15,605,903
Operating Expense
11,705,967
11,834,367
11,192,293
11,155,930
10,409,954
Operating Income
10,307,356
8,384,856
7,484,264
6,988,343
5,195,949
Net Non Operating Interest Income Expense
663,516
660,516
679,997
691,567
1,070,435
Pretax Income
11,719,279
8,161,879
8,364,000
7,790,481
4,539,905
Tax Provision
3,127,369
2,262,269
2,287,578
3,982,792
1,667,216
Net Income Common Stockholders
8,591,910
5,899,610
6,106,868
16,947,193
3,581,473
Diluted NI Available to Com Stockholders
8,591,910
5,899,610
6,106,868
16,947,193
3,581,473
Basic EPS
50.72
34.83
36.05
100.04
21.14
Diluted EPS
50.72
34.83
36.05
100.04
21.14
Basic Average Shares
169,425.22
169,406.03
169,406.03
169,406.03
169,406.03
Diluted Average Shares
169,425.22
169,406.03
169,406.03
169,406.03
169,406.03
Rent Expense Supplemental
--
20,052
20,979
18,129
20,972
Total Expenses
26,619,652
26,032,852
24,779,523
25,652,469
23,798,110
Net Income from Continuing & Discontinued Operation
8,591,910
5,899,610
6,106,868
16,947,193
3,581,473
Normalized Income
8,175,849.75
6,578,679.15
5,859,616.19
3,720,240.80
3,965,192.32
Interest Income
--
678,503
698,119
711,528
1,105,749
Interest Expense
14,987
17,987
18,122
19,961
35,314
Net Interest Income
663,516
660,516
679,997
691,567
1,070,435
EBIT
11,734,266
8,179,866
8,382,122
7,810,442
4,575,219
EBITDA
12,435,962
8,876,662
9,039,794
8,492,302
5,361,268
Reconciled Cost of Revenue
14,913,685
14,198,485
13,587,230
14,496,539
13,388,156
Reconciled Depreciation
701,696
696,796
657,672
681,860
786,049
Net Income from Continuing Operation Net Minority Interest
8,591,910
5,899,610
6,076,422
3,807,689
2,872,689
Total Unusual Items Excluding Goodwill
567,502
-939,498
298,384
124,926
-1,726,557
Total Unusual Items
567,502
-939,498
298,384
124,926
-1,726,557
Normalized EBITDA
11,868,460
9,816,160
8,741,410
8,367,376
7,087,825
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
151,441.75
-260,428.85
81,578.19
37,477.80
-634,053.68
3/31/2021 - 1/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BRM.MU Bristol-Myers Squibb Co
43.73
-0.08%
 
MRK.MX Merck & Co., Inc.
1,560.00
-2.80%
 
NOTA.BE Novartis AG
97.40
+3.18%
 
NOV.MU Novo Nordisk A/S
55.89
+0.47%
 
SNW.HM Sanofi SA
91.01
+1.03%
 
PFE.CL Pfizer Inc.
95,280.00
-2.60%
 
4AB.F AbbVie Inc.
151.60
-0.79%
 
NOTA.DU Novartis AG
96.00
-0.83%
 
AZNl.XC
 
BAYZF Bayer Aktiengesellschaft
23.65
0.00%